Safety and Feasibility of Riociguat Therapy for the Treatment of Chronic Pulmonary Arterial Hypertension in Infancy.

[1]  S. Berkelhamer,et al.  An update on the diagnosis and management of bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension. , 2018, Seminars in perinatology.

[2]  A. Torbicki,et al.  Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics. , 2018, International journal of cardiology.

[3]  A. Bos,et al.  Identification of gaps in the current knowledge on pulmonary hypertension in extremely preterm infants: A systematic review and meta‐analysis , 2018, Paediatric and perinatal epidemiology.

[4]  H. Gall,et al.  Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH , 2018, Lung.

[5]  A. Torbicki,et al.  Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension , 2016, Heart.

[6]  P. McNamara,et al.  Hemodynamic instability in the critically ill neonate: An approach to cardiovascular support based on disease pathophysiology. , 2016, Seminars in perinatology.

[7]  A. Sehgal,et al.  Sildenafil therapy in bronchopulmonary dysplasia-associated pulmonary hypertension: a retrospective study of efficacy and safety , 2015, European Journal of Pediatrics.

[8]  B. Hanna,et al.  Safety of Epoprostenol and Treprostinil in Children Less than 12 Months of Age , 2013, Pulmonary circulation.

[9]  Jan Marek,et al.  Targeted Neonatal Echocardiography in the Neonatal Intensive Care Unit: practice guidelines and recommendations for training. Writing Group of the American Society of Echocardiography (ASE) in collaboration with the European Association of Echocardiography (EAE) and the Association for European Pedi , 2011, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[10]  D. McElhinney,et al.  Pulmonary Artery Hypertension in Formerly Premature Infants With Bronchopulmonary Dysplasia: Clinical Features and Outcomes in the Surfactant Era , 2007, Pediatrics.

[11]  O. V. Evgenov,et al.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential , 2006, Nature Reviews Drug Discovery.

[12]  Kazuki Nakamura,et al.  Disturbances in nitric oxide/cyclic guanosine monophosphate system in SHR/NDmcr-cp rats, a model of metabolic syndrome. , 2006, Life sciences.

[13]  W. Seeger,et al.  Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling , 2006, Circulation.

[14]  J. Wharton,et al.  Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. , 2005, American journal of respiratory and critical care medicine.

[15]  K. Stenmark,et al.  Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesis , 2004, The Pediatric infectious disease journal.

[16]  D. Harrison,et al.  Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. , 2003, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[17]  J. Stasch,et al.  Cardiorenal and Humoral Properties of a Novel Direct Soluble Guanylate Cyclase Stimulator BAY 41-2272 in Experimental Congestive Heart Failure , 2003, Circulation.

[18]  W. Seeger,et al.  Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial , 2002, The Lancet.

[19]  A. Bush,et al.  Changes in pulmonary circulation in severe bronchopulmonary dysplasia. , 1990, Archives of disease in childhood.

[20]  J. Fouron,et al.  Value of echocardiography in assessing the outcome of bronchopulmonary dysplasia of the newborn. , 1980, Pediatrics.

[21]  J. Stasch,et al.  NO-independent, haem-dependent soluble guanylate cyclase stimulators. , 2009, Handbook of experimental pharmacology.